Skip to content
10-Q/A

Quarterly Report

Eastgate Biotech Corp

0001640334-18-000410

← back to feed
Filed
Mar 1, 2018 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2016 · Feb 28, 2018 934.31M sh
Stockholders Equity restated Q3 2016 · Sep 30, 2016 −$4.15M
Stockholders Equity Q3 2016 · Dec 31, 2015 −$2.48M
Stockholders Equity Q3 2016 · Dec 31, 2014 −$1.4M
Current Liabilities restated Q3 2016 · Sep 30, 2016 $4.1M
Current Liabilities Q3 2016 · Dec 31, 2015 $2.73M
Total Liabilities restated Q3 2016 · Sep 30, 2016 $4.15M
Total Liabilities Q3 2016 · Dec 31, 2015 $2.78M
Current Assets restated Q3 2016 · Sep 30, 2016 $0
Current Assets Q3 2016 · Dec 31, 2015 $113.52K
Total Assets restated Q3 2016 · Sep 30, 2016 $0
Total Assets Q3 2016 · Dec 31, 2015 $297.92K
Sga Expense restated Q3 2016 · Sep 30, 2016 $234.07K
Sga Expense restated Q3 2016 · Sep 30, 2016 $1.5M
Sga Expense Q3 2016 · Sep 30, 2015 $464.76K
Sga Expense Q3 2016 · Sep 30, 2015 $1.97M
Rd Expense restated Q3 2016 · Sep 30, 2016 $115.61K
Rd Expense restated Q3 2016 · Sep 30, 2016 $381.12K
Rd Expense Q3 2016 · Sep 30, 2015 $257.38K
Rd Expense Q3 2016 · Sep 30, 2015 $951.36K
Net Income restated Q3 2016 · Sep 30, 2016 −$473.3K
Net Income restated Q3 2016 · Sep 30, 2016 −$2.41M
Net Income Q3 2016 · Dec 31, 2015 −$4.28M
Net Income Q3 2016 · Sep 30, 2015 −$835.82K
Net Income Q3 2016 · Sep 30, 2015 −$3.46M
Operating Income restated Q3 2016 · Sep 30, 2016 −$433.52K
Operating Income restated Q3 2016 · Sep 30, 2016 −$2.11M
Operating Income Q3 2016 · Sep 30, 2015 −$806.37K
Operating Income Q3 2016 · Sep 30, 2015 −$3.38M
Cash And Equivalents Q3 2016 · Dec 31, 2015 $19.24K
Cash And Equivalents Q3 2016 · Dec 31, 2014 $286.48K
Gross Profit Q3 2016 · Sep 30, 2015 $62.12K
Gross Profit Q3 2016 · Sep 30, 2015 $112.23K